文献速递胰腺与胆道疾病消化内镜

高危人群经直肠吲哚美辛预防ERCP后胰腺炎时代的真实世界实践模式

Real-World Practice Patterns in the Era of Rectal Indomethacin for Prophylaxis Against Post-ERCP Pancreatitis in a High-Risk Cohort.
PubMed 文献 · Am J Gastroenterol · 2020-01-01

研究期间总体PEP率为8.6%,2012至2018年PEP率无下降;吲哚美辛使用自2012年起线性增加(P < 0.001),但2018年仍低于50%;胰管支架使用从2013至2014年骤降(40.7%-8.5%),后降至最低点3.0%。作者认为需进一步教育和质量保证措施以确保直肠吲哚美辛和胰管支架更恰当使用。

要点

  • 高危ERCP队列总体PEP率为8.6%,2012至2018年PEP率无下降。
  • 吲哚美辛使用自2012年起线性增加(P < 0.001),但2018年仍低于50%。
  • 胰管支架使用从2013至2014年骤降(40.7%-8.5%),后降至最低点3.0%。

核心结论

  • 尽管直肠吲哚美辛低成本、广泛可及且有I级证据支持在高危患者中降低PEP风险,其在ERCP期间的采用缓慢且该药物仍未被充分利用。
  • 同期胰管支架使用大幅下降;研究期间PEP率无变化可能归因于直肠吲哚美辛持续低使用或胰管支架使用下降。
  • 作者认为需进一步教育和质量保证措施以确保直肠吲哚美辛和胰管支架放置在临床实践中更恰当使用。

研究设计与样本

  • 数据提取自商业数据库(Explorys, IBM Watson Health, Somers, NY),该数据库汇总了2009至2018年美国26个医疗系统的电子健康记录。
  • 使用医学系统化命名法临床术语(SNOMED CT)识别接受ERCP且基于窄标准为PEP高危的患者队列。
  • PEP定义为ERCP后1-5天急诊科或医院入院并伴有胰腺炎相关诊断。

主要发现

  • 研究期间总体PEP率为8.6%。
  • 2012至2018年PEP率无下降。
  • 吲哚美辛使用自2012年起线性增加(P < 0.001),但2018年仍低于50%。
  • 随着吲哚美辛使用增加,胰管支架使用从2013至2014年骤降(40.7%-8.5%),后降至最低点3.0%。

关键数值与推荐

  • PEP定义为ERCP后1-5天急诊科或医院入院并伴有胰腺炎相关诊断。
  • 高危患者基于窄标准识别。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: The benefit of indomethacin suppositories for prophylaxis against post-ERCP pancreatitis (PEP) in high-risk patients was established in a landmark trial published in 2012. The aims of this study were to measure the adoption of indomethacin prophylaxis in widespread clinical practice, evaluate concurrent trends in pancreatic duct (PD) stent utilization, and estimate the impact of these changes on PEP in a high-risk population. METHODS: Data were extracted from a commercial database (Explorys, IBM Watson Health, Somers, NY) that aggregates electronic health records from 26 US healthcare systems from 2009 to 2018. Using Systematized Nomenclature of Medicine Clinical Terms, we identified a cohort of patients who underwent endoscopic retrograde cholangiopancreatography (ERCP) and were at high risk for PEP based on narrow criteria. PEP was defined as an emergency department or hospital admission 1-5 days after ERCP with an associated diagnosis of pancreatitis. RESULTS: Twenty six thousand eight hundred twenty ERCPs were performed on this high-risk cohort from 2009 to 2018. The overall PEP rate during the study period was 8.6%. There was no decrease in PEP rates from 2012 to 2018. Beginning in 2012, indomethacin usage increased linearly (P < 0.001), but remained below 50% in 2018. As indomethacin increased, utilization of PD stents declined abruptly from 2013 to 2014 (40.7%-8.5%) and trended to a nadir of 3.0%. DISCUSSION: Despite its low cost, widespread availability, and level I evidence of benefit in reducing the risk of PEP in high-risk patients, the adoption of rectal indomethacin during ERCP has been slow and the medication continues to be under-utilized. In parallel, the PD stent usage has declined dramatically. The lack of change in PEP rates during the study period could be attributable to the persistent low usage of rectal indomethacin or the decline in PD stent use. Further educational efforts and quality assurance measures are warranted to ensure that rectal indomethacin and PD stent placement are more appropriately used in clinical practice.

来源:Am J Gastroenterol,查看原文。版权归原作者所有。

引用

  1. Smith ZL, Elmunzer BJ, Cooper GS, et al. Real-World Practice Patterns in the Era of Rectal Indomethacin for Prophylaxis Against Post-ERCP Pancreatitis in a High-Risk Cohort. Am J Gastroenterol. 2020. PMID: 32496740. doi:10.14309/ajg.0000000000000623

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。